Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B

Microbiological Research

Volumn 163, Issue 4, 2008, Pages 487-492

  Feng, Bo ^a   Wei, Lai ^a   Chen, Ming ^b   Wang, Liping ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Polymerase gene; YMDD mutation

Indexed keywords

CHAIN LENGTH; DNA; GENES; NUCLEIC ACIDS; ORGANIC ACIDS; PLANTS (BOTANY); TURBULENT FLOW; VIRUSES;

CHRONIC HEPATITIS; DNA FRAGMENTS; DYNAMIC CHANGES; ELSEVIER (CO); HEPATITIS B VIRUS (HBV); LAMIVUDINE; LAMIVUDINE TREATMENT; PCR-RFLP; POLYMERASE CHAIN REACTION (RT-PCR); POLYMERASE GENES; RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLM); SERUM SAMPLES;

CLONING;

DISEASE RESISTANCE; DISEASE TREATMENT; GENE; HEPATITIS; MUTATION; POLYMERASE CHAIN REACTION;

HEPATITIS B VIRUS;

EID: 44849128244     PISSN: 09445013     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micres.2006.11.004     Document Type: Article

References (15)

1. Alberti A., Brunetto M.R., Colombo M., and Craxi A. Recent progress and new trends in the treatment of hepatitis B. J Med Virol 67 (2002) 458-462
2. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677
3. Chen C.H., Lee C.M., Lu S.N., Wang J.H., Tung H.O., Hung C.H., et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 41 (2004) 454-461
4. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
5. Hoofnagle J.H., and Bisceglie A.M.D. The treatment of chronic viral hepatitis. N Engl J Med 336 (1997) 347-356
6. Lai C.L., Chien R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
7. Leung N.W., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
8. Liang W.F., Yang D.H., Shen Y.H., Xie Y.J., and Zhao N.F. Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment. Chin J Hepatol 11 (2003) 302-304
9. Liaw Y.F., Leung N., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. Gastroenterology 199 (2000) 172-180
10. Matsuda M., Suzuki F., Suzuki Y., Tsubota A., Akuta N., Hosaka T., et al. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 39 (2004) 34-40
11. Ono-Nita S.K., Kato N., Shiratori Y., Masaki T., Lan K.H., Carrilho F.J., et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine: a study by in vitro full-length viral DNA transfection. Hepatology 29 (1999) 939-945
12. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36 (2002) 186-194
13. Thakur V., Sarin S.K., Rehman S., Guptan R.C., Kazim S.N., and Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol 24 (2005) 12-15
14. Wang J.H., Lu S.N., Lee J.F., and Chou Y.P. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 37 (2002) 366-369
15. Yao G.B., Cui Z.Y., Wang B.E., Yao G.L., and Zeng M.D. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Hepatobiliary Pancreatic Dis Int 3 (2004) 188-193